Biosimilars/Biobetters Pipeline Database        
The most comprehensive and cost-effective follow-on biopharmaceuticals (biosimilars, biobetters and biogenerics) pipeline resource 

  • Find competing products and companies; product/API licensing sources; collaborators and partners; or customers for your products, technologies and services
  • Over 1,450 product records:  >800 biosimilars, nearly 500 biobetters, >140 reference products; plus >650 involved company records
  • Online subscription databases - Products and Companies, with links between them
  • From the author of BIOPHARMA:  Biopharmaceuticals in the U.S. and European Markets, "The Reference Products' Reference," the only information resource/reference specializing in biopharmaceuticals. 
  • Satisfaction guaranteed!  Full refund within 1 month, e.g., if you do not learn information that critically affects your company.

Description/Flyer:  Further information
Users Guide
Contact/Order/Inquiry form
Enter password for database access:

Biosimilars/Biobetters Pipeline Database - Top Level Data (3/8/2016)

  • total product entries = 1357
  • total pipeline products (biosimilars + biobetters) = 1219
  • biosimilars = 737
  • biobetters = 482
  • ref. products = 137
  • biogenerics (in dev. countries) = ~200 (classed as biosimilars)
The database only covers recombinant proteins and a few other protein products.  Biosimilar and biobetter U.S. and EU launchable dates (patent expiration and data and market exclusivity expirations) are reported for all >130 reference products are reported in BIOPHARMA, "The Reference Products Reference."  Note, in addition to the over 730 biosimilars reported in the pipeline , nearly 200 "biogenerics" in non- and lesser-regulated international commerce are identified and loosely classed at this top level as "biosimilars."

Near-term economic impact includes over 40, nearly all recombinant, mostly monoclonal antibody, products with over $1 billion/year sales, and about 20 others with sales over $500 million/year. 

Follow-on products containing rather (bio)similar active agents are classed as either biosimilar (much the same, including approvable as biosimilars) or biobetter (too different to be approved as a biosimilar).  There are still relatively few genuine biosimilars (by US/EU standards), i.e., products approved by a formal biosimilar mechanism, mostly in Europe.  Biogenerics are the subset of biosimilars primarily oriented to lesser-regulated, developing country markets.  The great majority of biogenerics are currently marketeted internationally, with their development pipeline rather small compared to major market-oriented biosimilars.

Note, multiple companies can be involved with each product.

Some Popular Targeted Reference Products
[No. of biosimilars by reference product]
Humira 30
Remicade 17
Epoetin alfa 85
Neupogen 59
Neulasta 24
Enbrel 31
Rituxan 50
Herceptin 38
Lantus 10
Avastin 25
Insulin and analogs 51
Interferons (alfa) 60
Interferons (beta) 27
Somatropins 34
Cancer indications 418
mAbs, mAb fragments      261

Companies With the Largest Biosimilars Pipelines
Biosimilars (10 or more)
Harvest Moon Pharmaceuticals USA, Inc. 28
BioXpress Therapeutics S.A. 19
Zydus Cadilla Healthcare Ltd. 17
Biocon Ltd. 17
Mylan Labs. 14
Inbiopro Solutions Pvt Ltd. 14
Creative Biomart Inc. 13
Green Cross Corp. 12
Bio Sidus S.A. 12
AXXO GmbH 12
Dong-A Pharmaceutical. 12
Bioton S.A.. 11
Chemo Group (Grupo Insud ) 11
Novartis AG 10
LG Life Sciences Ltd. 10
Amega Biotech 10
Cassara Biotech 10
Note, about 50% of those companies claiming the most biosimilars in their pipeline and/or marketed are not currently manufacturing to US/EU cGMP standards (due to biogenerics being classed as biosimilars for top-line data analyses). Information Resources A variety of unique follow-on biopharmaceutical-related information resources are available or planned:

Some related articles by the database author:

Need a Consultant With Biosimilars Expertise? - Contact Biotechnology Information Institute for world-class expertise concerning biopharmaceutical information, products, technologies, and related market, technology and policy assessments.